Paper 24 - A PHASE IB STUDY TO EVALUATE THE FEASIBILITY OF NIVOLUMAB OR NIVOLUMAB WITH AZACITIDINE IN PATIENTS WITH RECURRENT, RESECTABLE OSTEOSARCOMA: A REPORT FROM THE NATIONAL PEDIATRIC CANCER FOUNDATION

Author(s)

• MC

  Matthew E. Campbell, MD

  Assistant Professor
  University of Texas Southwestern Medical Center
  Dallas, Texas, United States

  Slides

Co-Author(s)

• BF

  Brooke Fridley, PhD

  Children's Mercy
  Kansas City, Missouri, United States
• VY

  Vivien Yin, PhD

  Moffitt Cancer Center
  Tampa, Florida, United States
• JC

  Jessica Crimella, BSN, RN, CCRP

  Moffitt Cancer Center
  Tampa, Florida, United States
• JW

  Junmin Whiting, PhD

  Moffitt Cancer Center
  Tampa, Florida, United States
• JO

  Javier Oesterheld, MD

  Carolina Medical Center, Levine Cancer Institute
  Charlotte, North Carolina, United States
• JL

  Joanne Lagmay, MD

  Shand's Hospital for Children at the University of Florida
  Gainesville, Florida, United States
• BS

  Bhuvana Setty, MD

  Nationwide Children's Hospital
  Columbus, Ohio, United States
• SB

  Scott C. Borinstein, MD, PhD

  Vanderbilt University Medical Center
  Nashville, Tennessee, United States
• MI

  Michael Isakoff, MD

  Connecticut Children's Medical Center
  Hartford, Connecticut, United States
• TB

  Thomas C. Badgett, MD, PhD

  University of Kentucky
  Lexington, Kentucky, United States
• ES

  Eric Sandler, MD

  Nemours Children's Hospital
  Jacksonville, Florida, United States
• BL

  Brian Ladle, MD, PhD

  Johns Hopkins University
  Baltimore, Maryland, United States
• AG

  Ajay Gupta, MD

  Roswell Park Comprehensive Cancer Center
  Buffalo, New York, United States
• LW

  Lars Wagner, MD

  Duke University
  Durham, North Carolina, United States
• 

  Matteo Trucco, MD

  Associate Professor
  Cleveland Clinic
  Cleveland, Ohio, United States

Co-Author(s)

• 

  Jonathan Metts, MD

  Assistant Member, Sarcoma Department
  Moffitt Cancer Center
  Tampa, Florida, United States

Co-Author(s)

• DR

  Damon Reed, MD

  Memorial Sloan Kettering
  New York, New York, United States
• NL

  Nicolas Llosa, MD

  Johns Hopkins University
  Baltimore, Maryland, United States
• MD

  Mihaela Druta, MD

  Vice Chair Sarcoma Department
  Moffitt Cancer Center & Research Institute
  Tampa, Florida, United States
• PT

  Patrick Thompson, MD

  University of North Carolina at Chapel Hill
  Chapel Hill, North Carolina, United States